6431 related articles for article (PubMed ID: 3091371)
21. Potentiation by alpha-difluoromethylornithine of the activity of 3,4-dihydroxybenzylamine, a tyrosinase-dependent melanolytic agent, against B16 melanoma.
Prakash NJ; Sunkara PS; Sjoerdsma A
Biochem Pharmacol; 1985 Jun; 34(11):1887-90. PubMed ID: 3924051
[TBL] [Abstract][Full Text] [Related]
22. Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.
Carbone PP; Douglas JA; Larson PO; Verma AK; Blair IA; Pomplun M; Tutsch KD
Cancer Epidemiol Biomarkers Prev; 1998 Oct; 7(10):907-12. PubMed ID: 9796636
[TBL] [Abstract][Full Text] [Related]
23. Synergistic antiproliferative activity of leukocyte interferon in combination with alpha-difluoromethylornithine against human cells in culture.
Rosenblum MG; Gutterman JU
Cancer Res; 1984 Jun; 44(6):2339-40. PubMed ID: 6426779
[TBL] [Abstract][Full Text] [Related]
24. [Therapy with inhibitors of polyamine biosynthesis in refractory prostatic carcinoma. An experimental and clinical study].
Dunzendorfer U; Knöner M
Onkologie; 1985 Aug; 8(4):196-200. PubMed ID: 2419811
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of weekly high-dose human lymphoblastoid interferon.
Connors JM; Silver HK
Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
[TBL] [Abstract][Full Text] [Related]
26. Effect of murine alpha-, beta-, and gamma-interferons in combination with alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the tumor growth and metastasis of B16 melanoma and Lewis lung carcinoma in mice.
Sunkara PS; Bowlin TL; Rosenberger AL; Fleischmann WR
J Biol Response Mod; 1989 Apr; 8(2):170-9. PubMed ID: 2499664
[TBL] [Abstract][Full Text] [Related]
27. The in vitro interaction of alpha-difluoromethyl ornithine (DFMO) and several interferons on human cell lines.
Wolf LM; Leitzel KE; Pegg AE; Harvey HA; Lipton A
J Biol Response Mod; 1985 Aug; 4(4):391-5. PubMed ID: 3928826
[TBL] [Abstract][Full Text] [Related]
28. Enhancement of the antiproliferative activity of human interferon by polyamine depletion.
Kovach JS; Svingen PA
Cancer Treat Rep; 1985 Jan; 69(1):97-103. PubMed ID: 3917854
[TBL] [Abstract][Full Text] [Related]
29. [Antiproliferative activity of difluoromethylornithine and the factors decreasing its effectiveness in malignant growth].
Khomenko AK; Semeniĭ VIa; Gridina NIa; Diachok FI; Kudriavets IuI
Eksp Onkol; 1986; 8(3):61-4. PubMed ID: 3087732
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
[TBL] [Abstract][Full Text] [Related]
31. Phase I-II study of interferon-gamma and eflornithine (DFMO) in patients with advanced renal cell carcinoma, malignant melanoma and colorectal carcinoma.
Zeller W; Garbrecht M; Dierlamm J; Vogel I; Fiedler W; Hossfeld D
Oncol Rep; 1996 May; 3(3):447-51. PubMed ID: 21594390
[TBL] [Abstract][Full Text] [Related]
32. Effects of alpha-difluoromethylornithine on the growth of experimental Wilms' tumor and renal adenocarcinoma.
Kingsnorth AN; McCann PP; Diekema KA; Ross JS; Malt RA
Cancer Res; 1983 Sep; 43(9):4031-4. PubMed ID: 6307502
[TBL] [Abstract][Full Text] [Related]
33. Successful treatment with DL-alpha-difluoromethylornithine in established human small cell variant lung carcinoma implants in athymic mice.
Luk GD; Abeloff MD; Griffin CA; Baylin SB
Cancer Res; 1983 Sep; 43(9):4239-43. PubMed ID: 6409400
[TBL] [Abstract][Full Text] [Related]
34. Alpha-difluoromethylornithine as treatment for metastatic breast cancer patients.
O'Shaughnessy JA; Demers LM; Jones SE; Arseneau J; Khandelwal P; George T; Gersh R; Mauger D; Manni A
Clin Cancer Res; 1999 Nov; 5(11):3438-44. PubMed ID: 10589756
[TBL] [Abstract][Full Text] [Related]
35. The effect of combination treatment with alpha-difluoromethylornithine and Corynebacterium parvum on B16 melanoma growth and tumoricidal effector cell generation in vivo.
Bowlin TL; Rosenberger AL; Sunkara PS
Cancer Immunol Immunother; 1985; 20(3):214-8. PubMed ID: 3933819
[TBL] [Abstract][Full Text] [Related]
36. The effect of alpha-difluoromethylornithine on natural killer cell and tumoricidal macrophage induction by interferon in vivo.
Bowlin TL; Rosenberger AL; McKown BJ; Davis GF; Sunkara PS
Int J Immunopharmacol; 1986; 8(2):131-6. PubMed ID: 3086243
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of continuous-infusion alpha-difluoromethylornithine therapy for colorectal carcinoma.
Ajani JA; Ota DM; Grossie VB; Abbruzzese JL; Faintuch JS; Patt YZ; Jackson DE; Levin B; Nishioka K
Cancer Chemother Pharmacol; 1990; 26(3):223-6. PubMed ID: 2113439
[TBL] [Abstract][Full Text] [Related]
38. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
[TBL] [Abstract][Full Text] [Related]
39. Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme.
Levin VA; Uhm JH; Jaeckle KA; Choucair A; Flynn PJ; Yung WKA ; Prados MD; Bruner JM; Chang SM; Kyritsis AP; Gleason MJ; Hess KR
Clin Cancer Res; 2000 Oct; 6(10):3878-84. PubMed ID: 11051233
[TBL] [Abstract][Full Text] [Related]
40. Treatment of metastatic Lewis lung carcinoma with DL-alpha-difluoromethylornithine.
Bartholeyns J
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):567-72. PubMed ID: 6407845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
